Solving the dilemma of antimycobacterial chemotherapy.
Rastogi
N
N
Tuberculosis and Mycobacteria Unit, Institut Pasteur de la Guadeloupe, Pointe-a-Pitre, Guadeloupe, French West Indies.
Falkinham
J O
JO
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002991:Clofazimine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D009154:Mutation; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy* / Q000235:genetics
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000995:Antitubercular Agents; D002991:Clofazimine; D007538:Isoniazid